Caseware UK (AP4) 2024.0.164 2024.0.164 2024-08-312024-08-312025-05-2322023-09-01falseNo description of principal activity2truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07254575 2023-09-01 2024-08-31 07254575 2022-09-01 2023-08-31 07254575 2024-08-31 07254575 2023-08-31 07254575 c:Director1 2023-09-01 2024-08-31 07254575 d:FurnitureFittings 2023-09-01 2024-08-31 07254575 d:FurnitureFittings 2024-08-31 07254575 d:FurnitureFittings 2023-08-31 07254575 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-09-01 2024-08-31 07254575 d:OfficeEquipment 2023-09-01 2024-08-31 07254575 d:OfficeEquipment 2024-08-31 07254575 d:OfficeEquipment 2023-08-31 07254575 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-09-01 2024-08-31 07254575 d:OtherPropertyPlantEquipment 2023-09-01 2024-08-31 07254575 d:OtherPropertyPlantEquipment 2024-08-31 07254575 d:OtherPropertyPlantEquipment 2023-08-31 07254575 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2023-09-01 2024-08-31 07254575 d:OwnedOrFreeholdAssets 2023-09-01 2024-08-31 07254575 d:CurrentFinancialInstruments 2024-08-31 07254575 d:CurrentFinancialInstruments 2023-08-31 07254575 d:CurrentFinancialInstruments d:WithinOneYear 2024-08-31 07254575 d:CurrentFinancialInstruments d:WithinOneYear 2023-08-31 07254575 d:ShareCapital 2024-08-31 07254575 d:ShareCapital 2023-08-31 07254575 d:RetainedEarningsAccumulatedLosses 2024-08-31 07254575 d:RetainedEarningsAccumulatedLosses 2023-08-31 07254575 c:OrdinaryShareClass1 2023-09-01 2024-08-31 07254575 c:OrdinaryShareClass1 2024-08-31 07254575 c:OrdinaryShareClass1 2023-08-31 07254575 c:FRS102 2023-09-01 2024-08-31 07254575 c:AuditExempt-NoAccountantsReport 2023-09-01 2024-08-31 07254575 c:FullAccounts 2023-09-01 2024-08-31 07254575 c:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 07254575 d:WithinOneYear 2024-08-31 07254575 d:WithinOneYear 2023-08-31 07254575 d:BetweenOneFiveYears 2024-08-31 07254575 d:BetweenOneFiveYears 2023-08-31 07254575 e:PoundSterling 2023-09-01 2024-08-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 07254575









CAMBRIDGE PROTEIN ARRAYS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 AUGUST 2024

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
REGISTERED NUMBER: 07254575

BALANCE SHEET
AS AT 31 AUGUST 2024

2024
2024
2023
2023
Note
£
£
£
£

FIXED ASSETS
  

Tangible assets
 4 
464
444

CURRENT ASSETS
  

Stocks
 5 
31,548
11,934

Debtors: amounts falling due within one year
 6 
88,507
67,806

Cash at bank and in hand
  
694,529
741,924

  
814,584
821,664

Creditors: amounts falling due within one year
 7 
(76,780)
(85,361)

NET CURRENT ASSETS
  
 
 
737,804
 
 
736,303

  

NET ASSETS
  
738,268
736,747


CAPITAL AND RESERVES
  

Called up share capital 
 8 
1
1

Profit and loss account
  
738,267
736,746

  
738,268
736,747


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

Page 1

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
REGISTERED NUMBER: 07254575
    
BALANCE SHEET (CONTINUED)
AS AT 31 AUGUST 2024

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




M J Taussig
Director

Date: 23 May 2025

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

1.


GENERAL INFORMATION

Cambridge Protein Arrays Limited is a private company limited by shares and incorporated in England and Wales. Its registered office is Babraham Hall, Babraham Research Campus, Cambridge, CB22 3AT.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

TURNOVER

Turnover comprises revenue recognised by the Company in respect of biotechnology consultancy sevices during the year, exclusive of Value Added Tax and trade discounts. Revenue is recognised as the fair value of the consideration received or receivable and is recognised based on invoice date.

 
2.3

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
25%
Office equipment
-
33%
Other fixed assets
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.4

STOCKS

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

Page 3

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.5

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.8

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

 
2.9

DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

 
2.10

OPERATING LEASES

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Page 4

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.11

PENSIONS

DEFINED CONTRIBUTION PENSION PLAN

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.12

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.



3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).

Page 5

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

4.


TANGIBLE FIXED ASSETS





Fixtures and fittings
Office equipment
Other fixed assets
Total

£
£
£
£



COST OR VALUATION


At 1 September 2023
533
7,322
17,200
25,055


Additions
-
363
-
363



At 31 August 2024

533
7,685
17,200
25,418



DEPRECIATION


At 1 September 2023
533
6,878
17,200
24,611


Charge for the year on owned assets
-
343
-
343



At 31 August 2024

533
7,221
17,200
24,954



NET BOOK VALUE



At 31 August 2024
-
464
-
464



At 31 August 2023
-
444
-
444


5.


STOCKS

2024
2023
£
£

Finished goods and goods for resale
31,548
11,934



6.


DEBTORS

2024
2023
£
£


Trade debtors
18,774
20,720

Other debtors
64,259
40,320

Prepayments and accrued income
5,474
6,766

88,507
67,806


Page 6

 
CAMBRIDGE PROTEIN ARRAYS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

7.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024
2023
£
£

Trade creditors
25,373
53,755

Other taxation and social security
4,303
-

Other creditors
26,193
10,881

Accruals and deferred income
20,911
20,725

76,780
85,361


Other creditors include contributions of £257 (2023 - £257) payable to the Company's defined contribution pension scheme at the balance sheet date.


8.


SHARE CAPITAL

2024
2023
£
£
ALLOTTED, CALLED UP AND FULLY PAID



1 (2023 - 1) Ordinary share of £1
1
1



9.


COMMITMENTS UNDER OPERATING LEASES

At 31 August 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2024
2023
£
£


Not later than 1 year
28,637
30,345

Later than 1 year and not later than 5 years
-
27,816

28,637
58,161

 
Page 7